8CC.F COCRYSTAL PHARMA NEW O.N.
- Market cap
- EUR 17.3M
- P/E
- -
- P/B
- 19.77x
- ROE
- -1,046.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 8CC.F undervalued?
Graham numberThe Graham number of COCRYSTAL PHARMA NEW O.N. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
COCRYSTAL PHARMA NEW O.N. fundamental analysis
No fundamental analysis for COCRYSTAL PHARMA NEW O.N. yet.
COCRYSTAL PHARMA NEW O.N. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About COCRYSTAL PHARMA NEW O.N.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhi…
Full company profileCOCRYSTAL PHARMA NEW O.N. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
COCRYSTAL PHARMA NEW O.N. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 660K |
| Operating Income | -14.2M | -18.1M | -21.2M | -17.9M | -9.02M | -11.1M |
| EBITDA | - | -17.7M | -21.2M | -17.4M | -8.64M | -11.0M |
| Net Income | -14.2M | -38.8M | -18.0M | -17.5M | -8.83M | -10.9M |
| EPS | -1.75 | -4.77 | -1.77 | -1.72 | -0.64 | -0.79 |
| Balance Sheet | ||||||
| Total Assets | 79.4M | 40.8M | 31.3M | 13.5M | 9.71M | 4.65M |
| Total Liabilities | 1.84M | 1.27M | 4.88M | 3.93M | 3.38M | 3.61M |
| Shareholders' Equity | 77.5M | 39.6M | 26.4M | 9.52M | 6.33M | 1.04M |
| Cash & Short-term Investments | 58.7M | 37.1M | 26.4M | 9.86M | 7.03M | 2.17M |
| Cash Flow | ||||||
| Operating Cash Flow | -12.7M | -21.4M | -14.7M | -16.5M | -8.19M | -9.71M |
| Capital Expenditure | 52.0K | 74.0K | 118K | 8.00K | 12.0K | 0.00 |
| Free Cash Flow | -12.8M | -21.5M | -14.8M | -16.5M | -8.20M | -9.71M |
| Ratios | ||||||
| ROE | -18.3% | -98.2% | -68.2% | -183.8% | -139.5% | -1,046.6% |
| ROA | -17.9% | -95.1% | -57.5% | -130.1% | -90.9% | -235.0% |
| Net Profit Margin | - | - | - | - | - | -1,655.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
COCRYSTAL PHARMA NEW O.N. dividends
COCRYSTAL PHARMA NEW O.N. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:12 on Oct 11, 2022.
Who owns COCRYSTAL PHARMA NEW O.N.
- Insiders 22.40%
- Institutions 5.96%
- Public & others 71.64%
- Shares outstanding 19.3M
- Free float 14.6M
COCRYSTAL PHARMA NEW O.N. company profile
- Company name
- COCRYSTAL PHARMA NEW O.N.
- Ticker
- 8CC.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- 19805 North Creek Parkway, Bothell, WA, United States, 98011
- Phone
- 877 262 7123
- Website
- cocrystalpharma.com
About COCRYSTAL PHARMA NEW O.N.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.
COCRYSTAL PHARMA NEW O.N. management
4- Prof. Roger D. Kornberg Ph.D.Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board · born 1947
- Dr. Sam Lee Ph.D.Chief Scientific Officer, Co-Founder & President · born 1960
- Mr. James J. Martin CPA, M.B.A.CFO & Corporate Secretary · born 1967
- Mr. James R. Sapirstein M.B.A., R.Ph.Chief Executive Officer · born 1961